rybrevant
janssen-cilag international n.v. - amivantamab - carcinom, ikke-småcellet lunge - antineoplastiske midler - rybrevant as monotherapy is indicated for treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with activating epidermal growth factor receptor (egfr) exon 20 insertion mutations, after failure of platinum-based chemotherapy.
tepmetko
merck europe b.v. - tepotinib hydrochloride monohydrate - carcinom, ikke-småcellet lunge - antineoplastiske midler - tepmetko as monotherapy is indicated for the treatment of adult patients with advanced non-small cell lung cancer (nsclc) harbouring alterations leading to mesenchymal-epithelial transition factor gene exon 14 (metex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.
tabrecta
novartis europharm limited - capmatinib dihydrochloride monohydrate - carcinom, ikke-småcellet lunge - antineoplastiske midler - tabrecta as monotherapy is indicated for the treatment of adult patients with advanced non small cell lung cancer (nsclc) harbouring alterations leading to mesenchymal epithelial transition factor gene exon 14 (metex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum based chemotherapy.
strefzap 8,75 mg/3 pust mundhulespray, opløsning
reckitt benckiser a/s - flurbiprofen - mundhulespray, opløsning - 8,75 mg/3 pust
strefzap honning og citron 8,75 mg/3 pust mundhulespray, opløsning
reckitt benckiser healthcare (scandinavia) a/s - flurbiprofen - mundhulespray, opløsning - 8,75 mg/3 pust
furix 40 mg tabletter
orifarm healthcare a/s - furosemid - tabletter - 40 mg
furix 20 mg tabletter
orifarm healthcare a/s - furosemid - tabletter - 20 mg
relifex 500 mg filmovertrukne tabletter
viatris aps - nabumeton - filmovertrukne tabletter - 500 mg
relifex 1 g opl?selige tabletter
viatris aps - nabumeton - opløselige tabletter - 1 g
avandamet
smithkline beecham plc - rosiglitazone, metformin-hydrochlorid - diabetes mellitus, type 2 - narkotika anvendt i diabetes - avandamet er indiceret til behandling af type 2-diabetes mellitus patienter, især overvægtige patienter:der ikke er i stand til at opnå tilstrækkelig glykæmisk kontrol ved deres maksimalt tolereret dosis af oral metformin alene. i triple oral behandling med sulphonylurea hos patienter med utilstrækkelig glykæmisk kontrol på trods af dobbelt oral behandling med deres maksimalt tolereret dosis af metformin og et sulphonylurea (se afsnit 4.